Initial experimental evidence that the ability to choose between items alters attraction to familiar versus novel persons in different ways for men and women

Nonhuman species may respond to novel mates with increased sexual motivation (‘The Coolidge Effect1). In humans, novel technological advances, such as online dating platforms, are thought to result in ‘Choice Overload’2. This may undermine the goal of finding a meaningful relationship3, orienting the user toward novel possible partners versus committing to a partner. Here, we used a paradigm measuring change in attraction to familiar faces (i.e. rated on second viewing4) to investigate Coolidge-like phenomena in humans primed with choice of potential online dating partners. We examined two pre-registered hypotheses (https://osf.io/xs74r/files/). First, whether experimentally priming choice (viewing a slideshow of online dating images) directly reduces the attractiveness of familiar preferred sex faces compared to our control condition. Second, whether the predicted effect is stronger for men than women given the role of the Coolidge effect in male sexual motivation5.<br/

Having options alters the attractiveness of familiar versus novel faces:sex differences and similarities

Although online dating allows us to access a wider pool of romantic partners, choice could induce an ‘assessment mindset’, orienting us toward ‘optimal’ or alternative partners and undermining our willingness to commit or remain committed to someone. Contextual changes in judgements of facial attractiveness can shed light on this issue. We directly test this proposal by activating a context where participants imagine choosing between items in picture slideshows (dates or equally attractive desserts), observing its effects on attraction to i) faces on second viewing and ii) novel versus familiar identities. Single women, relative to single men, were less attracted to the same face on second viewing (Experiments 2 and 4), with this sex difference only observed after imagining not ‘matching’ with any romantic dates in our slideshow (i.e., low choice, Experiment 4). No equivalent sex differences were observed in the absence of experimental choice slideshows (Experiment 3), and these effects (Experiment 2) were not moderated by slideshow content (romantic dates or desserts) or choice set size (five versus fifteen items). Following slideshows, novel faces were more attractive than familiar faces (Experiment 1), with this effect stronger in men than in women (Experiment 2), and stronger across both sexes after imagining ‘matching’ with desired romantic dates (i.e., high choice, Experiment 4). Our findings suggest that familiarity does not necessarily ‘breed liking’ when we have the autonomy to choose, revealing lower-order socio-cognitive mechanisms that could underpin online interactions, such as when browsing profiles and deciding how to allocate effort to different users

The social role of accounting: views and perceptions of the accounting community in Libya towards corporate social responsibility and accountability

The paper explores views and perceptions amongst members of the accounting community in Libya regarding the perceived basic features of the current corporate reporting and disclosure practices of the Libyan Business Organisations (LBOs). Extending these practices to embrace reporting and disclosure of social and environmental related information (CSR), and the extent to which notions of corporate social responsibility and accountability are acceptable in Libya are examined. Five groups of users of published accounts in Libya participated in the study, including academic accountants, financial managers (or accountants), government officials, bank credit officers and external auditors. A questionnaire survey of the 438 participants, drawing on the Al-khater and Naser (2003) study, was employed as the main data collection method. The findings demonstrate that currently most LBOs communicate limited information to a limited set of stakeholders. The disclosure of more social and environmental information was widely accepted and viewed as potentially leading to some beneficial socio-economic effects at the macro level. There was general agreement that the LBOs’ annual reports should reflect the interaction between their operations and the society in which they operate, recognizing the right of different stakeholders to information about the actions for which LBOs could be held responsible. The Law was viewed as the key source of establishing such responsibilities rather than professional guidelines

BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era

EAVE II is supported by the Medical Research Council (MR/R008345/1) with the support of BREATHE – The Health Data Research Hub for Respiratory Health, which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund [MC_PC_19004] and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and Scottish Government DG Health and Social Care, the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058) and the Lifelong Health and Well-being study as part of the National Core Studies (MC_PC_20030).Peer reviewedPublisher PD

An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene Interactions on risk of myocardial infarction: The importance of model validation

BACKGROUND: To examine interactions among the angiotensin converting enzyme (ACE) insertion/deletion, plasminogen activator inhibitor-1 (PAI-1) 4G/5G, and tissue plasminogen activator (t-PA) insertion/deletion gene polymorphisms on risk of myocardial infarction using data from 343 matched case-control pairs from the Physicians Health Study. We examined the data using both conditional logistic regression and the multifactor dimensionality reduction (MDR) method. One advantage of the MDR method is that it provides an internal prediction error for validation. We summarize our use of this internal prediction error for model validation. RESULTS: The overall results for the two methods were consistent, with both suggesting an interaction between the ACE I/D and PAI-1 4G/5G polymorphisms. However, using ten-fold cross validation, the 46% prediction error for the final MDR model was not significantly lower than that expected by chance. CONCLUSIONS: The significant interaction initially observed does not validate and may represent a type I error. As data-driven analytic methods continue to be developed and used to examine complex genetic interactions, it will become increasingly important to stress model validation in order to ensure that significant effects represent true relationships rather than chance findings

Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16:the SIVE II record linkage study

Background: There is good evidence of vaccine effectiveness in healthy individuals but less robust evidence for vaccine effectiveness in the populations targeted for influenza vaccination. The live attenuated influenza vaccine (LAIV) has recently been recommended for children in the UK. The trivalent influenza vaccine (TIV) is recommended for all people aged≥65 years and for those aged<65 years who are at an increased risk of complications from influenza infection (e.g. people with asthma). Objective: To examine the vaccine effectiveness of LAIV and TIV. Design: Cohort study and test-negative designs to estimate vaccine effectiveness. A self-case series study to ascertain adverse events associated with vaccination. Setting: A national linkage of patient-level general practice (GP) data from 230 Scottish GPs to the Scottish Immunisation & Recall Service, Health Protection Scotland virology database, admissions to Scottish hospitals and the Scottish death register. Participants: A total of 1,250,000 people. Interventions: LAIV for 2- to 11-year-olds and TIV for older people (aged≥65 years) and those aged<65 years who are at risk of diseases, from 2010/11 to 2015/16. Main outcome measures: The main outcome measures include vaccine effectiveness against laboratory-confirmed influenza using real-time reverse-transcription polymerase chain reaction (RT-PCR), influenza-related morbidity and mortality, and adverse events associated with vaccination. Results: Two-fifths (40%) of preschool-aged children and three-fifths (60%) of primary school-aged children registered in study practices were vaccinated. Uptake varied among groups [e.g. most affluent vs. most deprived in 2- to 4-year-olds, odds ratio 1.76, 95% confidence interval (CI) 1.70 to 1.82]. LAIV-adjusted vaccine effectiveness among children (aged 2-11 years) for preventing RT-PCR laboratoryconfirmed influenza was 21% (95% CI -19% to 47%) in 2014/15 and 58% (95% CI 39% to 71%) in 2015/16. No significant adverse events were associated with LAIV. Among at-risk 18- to 64-year-olds, significant trivalent influenza vaccine effectiveness was found for four of the six seasons, with the highest vaccine effectiveness in 2010/11 (53%, 95% CI 21% to 72%). The seasons with non-significant vaccine effectiveness had low levels of circulating influenza virus (2011/12, 5%; 2013/14, 9%). Among those people aged≥65 years, TIV effectiveness was positive in all six seasons, but in only one of the six seasons (2013/14) was significance achieved (57%, 95% CI 20% to 76%). Conclusions: The study found that LAIV was safe and effective in decreasing RT-PCR-confirmed influenza in children. TIV was safe and significantly effective in most seasons for 18- to 64-year-olds, with positive vaccine effectiveness in most seasons for those people aged≥65 years (although this was significant in only one season). Future work: The UK Joint Committee on Vaccination and Immunisation has recommended the use of adjuvanted injectable vaccine for those people aged≥65 years from season 2018/19 onwards. A future study will be required to evaluate this vaccine. Trial registration: Current Controlled Trials ISRCTN88072400